Physician profile
Emma Osterholzer
NPI 1942875893
$14,093.29
in general payments reported to CMS, 2019-2025
34 companies · $4,332 in 2025
The $4,332 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $241 · 2022: $2,335 · 2023: $3,177 · 2024: $4,008 · 2025: $4,332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $1,113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,403.96 |
| Education | $1,113.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,495.18 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $1,503.61 | 2021-2025 | Ilumya, Winlevi, Absorica Ld |
| Genzyme Corporation | $1,146.77 | 2021-2025 | |
| Janssen Biotech, INC. | $1,108.69 | 2023-2025 | Tremfya |
| Incyte Corporation | $1,047.41 | 2022-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $932.61 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $709.75 | 2022-2025 | Sotyktu |
| Amgen INC. | $616.60 | 2022-2025 | Otezla, Otezla |
| Ucb, INC. | $613.04 | 2021-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $602.51 | 2021-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $451.39 | 2022-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $398.21 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Pfizer INC. | $394.03 | 2022-2025 | |
| Galderma Laboratories, L.P. | $295.60 | 2021-2025 | Nemluvio, Aklief, Oracea |
| Dermavant Sciences, INC. | $252.49 | 2023-2024 | Vtama |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $242.81 | 2023-2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $162.14 | 2023-2025 | Spevigo |
| Sanofi-Aventis U.S. LLC | $159.94 | 2022-2023 | |
| Janssen Scientific Affairs, LLC | $155.50 | 2022 | |
| Mayne Pharma Commercial LLC | $148.47 | 2023-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $116.38 | 2021-2025 | Cabtreo |
| Organon LLC | $93.23 | 2023-2025 | Vtama, Hadlima |
| Journey Medical Corporation | $73.87 | 2022-2025 | |
| Smith+Nephew, INC. | $72.45 | 2023-2024 | Collagenase Santyl, Grafix Pl |
| Verrica Pharmaceuticals INC. | $72.04 | 2023-2025 | Ycanth |
| Organogenesis INC. | $65.14 | 2025 | Cygnus Dual, Simplimax |
| Convatec INC. | $28.72 | 2025 | |
| Almirall LLC | $22.59 | 2022 | |
| Mimedx Group, INC. | $22.31 | 2025 | |
| Genentech USA, INC. | $20.99 | 2022 | |
| Botanix Sb INC | $20.00 | 2025 | Sofdra |
| Lnhc, INC | $19.55 | 2025 | Zelsuvmi |
| Kerecis Limited | $14.72 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Strata Skin Sciences, INC. | $14.55 | 2025 | Xtrac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emma Osterholzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.